# Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine

> **NCT02643368** · PHASE4 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 760 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** mOPV2 at 6 and 7 weeks of age
- **BIOLOGICAL:** mOPV2 at 6 and 8 weeks of age
- **BIOLOGICAL:** mOPV2 at 6 and 10 weeks of age
- **BIOLOGICAL:** IPV at 6 weeks of age

## Key facts

- **NCT ID:** NCT02643368
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 760 (ACTUAL)
- **Last updated:** 2018-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02643368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02643368, "Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02643368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*